Angela Koehler
Founder at 76bio, Inc.
Profile
Angela Koehler is the founder of Ligon Discovery, Inc. (founded in 2007) and Kronos Bio, Inc. (founded in 2017).
Dr. Koehler holds a doctorate degree from Harvard University.
Dr. Koehler is also the founder of 76Bio, Inc.
Angela Koehler active positions
Companies | Position | Start |
---|---|---|
76bio, Inc.
76bio, Inc. Pharmaceuticals: MajorHealth Technology 76Bio, Inc. is a private company that aims to develop transformational therapies for patients with life-threatening diseases. The company is based in New York, NY. The company focuses on pioneering the next generation of degradation by design. 76Bio was founded by Joshua A. Kazam, David M. Tanen, Marius Pop, Christopher Wilfong, Ben Stone, Angela Koehler, Arie S. Belldegrun, and K. Dane Wittrup. Christopher Wilfong has been the CEO since incorporation. | Founder | - |
Former positions of Angela Koehler
Companies | Position | End |
---|---|---|
KRONOS BIO, INC. | Founder | - |
Ligon Discovery, Inc.
Ligon Discovery, Inc. Miscellaneous Commercial ServicesCommercial Services Ligon Discovery's primary technology platform, Small-Molecule Microarrays (SMMs), fundamentally transforms drug discovery by bringing the power of microarrays to target screening. SMMs, developed at Harvard University and the Broad Institute, use a proprietary surface chemistry to attach unmodified chemical collections to a solid surface, enabling massively-parallel screening against protein targets of any function. The scale and scope of SMMs permit a paradigmatic change in drug discovery strategy as entire protein families, molecular pathways, and even genome-wide target sets can be screened in parallel to rapidly identify small molecules with optimal characteristics for drug development. Ligon is applying SMM technology to challenging, novel targets aimed at discovery of first-in-class drugs for oncology and other selected diseases. Ligon Discovery's SMM platform is available for drug discovery collaborations. | Founder | - |
Training of Angela Koehler
Harvard University | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
KRONOS BIO, INC. | Health Technology |
Private companies | 2 |
---|---|
Ligon Discovery, Inc.
Ligon Discovery, Inc. Miscellaneous Commercial ServicesCommercial Services Ligon Discovery's primary technology platform, Small-Molecule Microarrays (SMMs), fundamentally transforms drug discovery by bringing the power of microarrays to target screening. SMMs, developed at Harvard University and the Broad Institute, use a proprietary surface chemistry to attach unmodified chemical collections to a solid surface, enabling massively-parallel screening against protein targets of any function. The scale and scope of SMMs permit a paradigmatic change in drug discovery strategy as entire protein families, molecular pathways, and even genome-wide target sets can be screened in parallel to rapidly identify small molecules with optimal characteristics for drug development. Ligon is applying SMM technology to challenging, novel targets aimed at discovery of first-in-class drugs for oncology and other selected diseases. Ligon Discovery's SMM platform is available for drug discovery collaborations. | Commercial Services |
76bio, Inc.
76bio, Inc. Pharmaceuticals: MajorHealth Technology 76Bio, Inc. is a private company that aims to develop transformational therapies for patients with life-threatening diseases. The company is based in New York, NY. The company focuses on pioneering the next generation of degradation by design. 76Bio was founded by Joshua A. Kazam, David M. Tanen, Marius Pop, Christopher Wilfong, Ben Stone, Angela Koehler, Arie S. Belldegrun, and K. Dane Wittrup. Christopher Wilfong has been the CEO since incorporation. | Health Technology |
- Stock Market
- Insiders
- Angela Koehler